5th Edition
Heparin-Induced Thrombocytopenia, Fifth Edition
Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most frequent and devastating adverse drug reactions encountered by physicians. This thoroughly updated fifth edition from international experts Professors Warkentin and Greinacher is the gold standard for accurate diagnosis and management of this condition. Identifying key signs and symptoms and providing clear intervention strategies—including the use of alternative anticoagulants to manage critical circumstances—this is an essential resource for all clinicians and a "must" for hematology consultants.
Heparin-Induced Thrombocytopenia, Fifth Edition explores:
- Clinical and laboratory studies on HIT
- The immune basis and pathogenesis, animal models, and laboratory testing for HIT antibodies
- Clinical features, differential diagnosis, scoring systems, and frequency of HIT in diverse clinical settings, including pediatric patients
- Evidence-based guidelines for recognition, treatment, and prevention
- Actions that should and should not be taken after the identification of HIT
- Traditional and novel pharmacotherapies, current dosing guidelines, and the advantages and limitations of alternative anticoagulants
- Selection criteria from a variety of new treatment options, helping physicians determine which of these agents are safe and effective for their patients
History of Heparin-Induced Thrombocytopenia
Theodore E. Warkentin
Clinical Picture of Heparin-Induced Thrombocytopenia
Theodore E. Warkentin
Differential Diagnosis of Heparin-Induced Thrombocytopenia and Scoring Systems
Theodore E. Warkentin, Adam Cuker, MD, MS
Frequency of Heparin-Induced Thrombocytopenia
Lori-Ann Linkins, David H. Lee
Nonimmune Heparin-Platelet Interactions: Implications for the Pathogenesis of Heparin-Induced Thrombocytopenia
McDonald K. Horne III, Andreas Greinacher
Role of Heparin-Dependent Antigens in Immune Heparin-Induced Thrombocytopenia
Jean Amiral, Anne Marie Vissac
Role of Sulfated Polysaccharides and other Polyanions in the Pathogenesis of Heparin-Induced Thrombocytopenia
Susanne Alban, Krystin Krauel, Andreas Greinacher
Platelet and Leukocyte Fcγ Receptors in Heparin-Induced Thrombocytopenia
Gregory A. Denomme
Cellular and Molecular Immunopathogenesis of Heparin-Induced Thrombocytopenia
Lubica Rauova, Gowthami M. Arepally
Murine Models of Heparin-Induced Thrombocytopenia
Gowthami M. Arepally, Bruce S. Sachais, Douglas B. Cines, Mortimer Poncz, Lubica Rauova, Steven E. McKenzie
Laboratory Testing for Heparin-Induced Thrombocytopenia
Theodore E. Warkentin, Andreas Greinacher
Treatment of Heparin-Induced Thrombocytopenia: An Overview
Andreas Greinacher, Theodore E. Warkentin
Argatroban Therapy in Heparin-Induced Thrombocytopenia
Lawrence Rice, Martin Beiderlinden, Marcie J. Hursting
Recombinant Hirudin for the Treatment of Heparin-Induced Thrombocytopenia
Andreas Greinacher
Bivalirudin for the treatment of Heparin-Induced Thrombocytopenia
John R. Bartholomew, Jayne Prats, PhD.
Danaparoid for the Treatment of Heparin-Induced Thrombocytopenia
Beng Hock Chong, Harry N. Magnani
Fondaparinux and Other Emerging Anticoagulants to Treat Heparin-Induced Thrombocytopenia
Theodore E. Warkentin, John W. Eikelboom
Hemodialysis in HIT
Karl-Georg Fischer
Management of Intraoperative Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiovascular Surgery
Sixten Selleng, Andreas Koster
Heparin-Coated Intravascular Devices and Heparin-Induced Thrombocytopenia
Theodore E. Warkentin
Heparin-Induced Thrombocytopenia in Children
Anne F. Klenner, Andreas Greinacher
A Clinician’s Perspective on Heparin-Induced Thrombocytopenia: Paradoxes, Myths, and Continuing Challenges
Lawrence Rice
Biography
Theodore E. Warkentin, MD, FACP, FRCPC is a professor in the Department of Pathology and Molecular Medicine, and the Department of Medicine, at McMaster University, Canada.
Prof. Dr. Andreas Greinacher is professor and head of the Department of Transfusion Medicine and the Hemostasis Service at the Medical School and Hospital of the Ernst-Moritz-Arndt-University Greifswald, CEO and chief of staff of the University Hospital Greifswald, and visiting professor at McMaster University Hamilton, Canada.
